<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="108059">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697579</url>
  </required_header>
  <id_info>
    <org_study_id>0517-029</org_study_id>
    <secondary_id>2012-002340-24</secondary_id>
    <nct_id>NCT01697579</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)</brief_title>
  <official_title>A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy Sub-title: Open-Label Cohort to Further Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients Birth to &lt;12 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the appropriate dosing regimen of fosaprepitant,
      when administered with ondansetron (with or without dexamethasone), for the prevention of
      CINV in children from birth to &lt;17 years of age. Fosaprepitant is a prodrug to aprepitant.
      All participants who complete the randomized Cycle 1 may elect to receive open-label
      fosaprepitant during optional Cycles 2-6.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Under Amendment 01, 0517-029 enrolled participants in the following age cohorts: 2-&lt;6, 6-&lt;12
      and 12-17 years old. The study was randomized, partially-blinded, with parallel group
      assignment. Participants were randomized to one of three fosaprepitant doses or the control
      group. (Amendment 02 and Amendment 03 were country-specific amendments in Brazil that were
      required as per local regulations with no change in study design.) Under Amendment 04, the
      12-17 year old cohort was closed since that cohort fully enrolled. An additional
      fosaprepitant dose was added and all participants were allocated to this one treatment
      group. Amendment 04 was open-label and enrolled participants in the following age cohorts:
      0-&lt;2, 2-&lt;6 and 6-&lt;12 years old.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2012</start_date>
  <completion_date type="Actual">November 21, 2016</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aprepitant Area Under the Curve from 0 to infinity (∞) hours (AUC 0-∞)</measure>
    <time_frame>Up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Maximum Concentration (Cmax)</measure>
    <time_frame>Up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Aprepitant Cmax (Tmax)</measure>
    <time_frame>Up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Terminal Phase Half-Life (t1/2)</measure>
    <time_frame>Up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Apparent Total Body Clearance (CL/F)</measure>
    <time_frame>Up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience At Least One Adverse Event</measure>
    <time_frame>Up to 14 days postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant AUC from 0 to 24 hours (AUC 0-24)</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Concentration at 24 hours (C24)</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Concentration at 48 hours (C48)</measure>
    <time_frame>Up to 48 hours postdose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Fosaprepitant 150 mg Adult Equivalent Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 150 mg (or age-adjusted equivalent for children &lt;12 years of age), administered intravenously (IV) plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or age-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-hydroxytryptamine 3 (5-HT3) antagonist. (Dosing closed by Amendment 04)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosaprepitant 60 mg Adult Equivalent Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 60 mg (or age-adjusted equivalent for children &lt;12 years of age), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or age-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-HT3 antagonist. (Dosing closed by Amendment 04)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosaprepitant 20 mg Adult Equivalent Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 20 mg (or age-adjusted equivalent for children &lt;12 years of age), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or age-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-HT3 antagonist. (Dosing closed by Amendment 04)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycle 1: Matching Placebo to fosaprepitant, administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-HT3 antagonist. (Dosing closed by Amendment 04)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosaprepitant 5 mg/kg Age-based Equivalent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 5 mg/kg (or age-adjusted equivalent for children &lt;4 months of age; not to exceed 150 mg), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 5 mg/kg mg (or age-adjusted equivalent for children &lt;4 months of age), administered IV plus a 5-HT3 antagonist. (Dosing initiated by Amendment 04)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant 150 mg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 150 mg Adult Equivalent Dose</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant 60 mg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 60 mg Adult Equivalent Dose</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant 20 mg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 20 mg Adult Equivalent Dose</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Fosaprepitant</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Fosaprepitant 150 mg Adult Equivalent Dose</arm_group_label>
    <arm_group_label>Fosaprepitant 60 mg Adult Equivalent Dose</arm_group_label>
    <arm_group_label>Fosaprepitant 20 mg Adult Equivalent Dose</arm_group_label>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Ondansetron hydrochloride</other_name>
    <other_name>Zofran® Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant 5 mg/kg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 5 mg/kg Age-based Equivalent</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is 0 months (at least 37 weeks gestation) to &lt;18 years of age

          -  Scheduled to receive chemotherapeutic agent(s) associated with moderate, high, or
             very high risk of emetogenicity for no more than 5 consecutive days for a documented
             malignancy, or a chemotherapy regimen not previously tolerated due to vomiting

          -  Expected to receive ondansetron as part of antiemetic regimen (Cycle 1); Expected to
             receive a 5-HT3 antagonist as part of antiemetic regimen (Cycles 2-6)

          -  If female and has begun menstruating, must have a negative pregnancy test prior to
             study participation and agree to remain abstinent or use a barrier form of
             contraception

          -  Predicted life expectancy of ≥3 months

          -  Pre-existing functioning central venous catheter

          -  Weight ≥3rd percentile for age and gender (and ≥3.0 kg)

        Exclusion Criteria:

          -  Vomited in the 24 hours prior study drug administration (Cycle 1)

          -  Current user of any illicit drugs (including marijuana) or current evidence of
             alcohol abuse

          -  Scheduled to receive stem cell rescue therapy in conjunction with study related
             course(s) of emetogenic chemotherapy

          -  Received or will receive radiation therapy to the abdomen or pelvis in the week prior
             to study drug administration and/or during the course of the study

          -  Pregnant or breast feeding

          -  Allergic to fosaprepitant, aprepitant, ondansetron, or any other 5-HT3 antagonist

          -  Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting

          -  Has an active infection, congestive heart failure, slow heart rate, or other
             uncontrolled disease other than cancer

          -  Mentally incapacitated or has a significant emotional or psychiatric disorder

          -  Known history of QT prolongation or is taking any medication known to lead to QT
             prolongation

          -  Taking other excluded medications

          -  Participated in any previous study of aprepitant or fosaprepitant, or taken an
             investigational drug within 4 weeks prior to study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
